Aberrant WNT5A DNA methylation has been reported throughout PrCa disease progression, with the WNT5A promoter shown to be hypermethylated in primary PrCa tumours when compared to benign prostatic hyperplasia24 and hypomethylated when compared to benign tissue.25 Here, WNT5A is linked to neoplasm.